English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/61838
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:


New drugs in multiple myeloma: mechanisms of action and phase I/II clinical findings

AuthorsOcio, Enrique M. ; Mateos, Maria Victoria; Maiso, Patricia; Pandiella, Atanasio ; San Miguel, Jesús F.
Issue Date2008
CitationLancet Oncology 9(12): 1157-1165 (2008)
AbstractThe outcome of multiple myeloma has substantially improved over the past decade, mainly due to recently approved drugs, such as thalidomide, lenalidomide, and bortezomib. Nevertheless, most patients still relapse and, therefore, drugs with new mechanisms of action are urgently needed to overcome this resistance. In this Review, we discuss some of the new targeted therapeutic strategies under assessment in preclinical and clinical studies in multiple myeloma. Unfortunately, the single-agent clinical activity of most of these new drugs has been limited; nevertheless, their effectiveness might be enhanced by their rational combination with each other or with conventional agents. © 2008 Elsevier Ltd. All rights reserved.
Identifiersdoi: 10.1016/S1470-2045(08)70304-8
issn: 1470-2045
e-issn: 1474-5488
Appears in Collections:(IBMCC) Artículos
Files in This Item:
File Description SizeFormat 
accesoRestringido.pdf15,38 kBAdobe PDFThumbnail
Show full item record
Review this work

Related articles:

WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.